were randomized to either anastrozole 1 mg daily or anastrozole plus trastuzumab with a loading dose of 4 mg/kg followed by 2 mg/kg once weekly until disease progression. Women whose cancer progressed during treatment with the single drug were offered the chance to switch to combination therapy, and 35% of the single-drug arm switched to combination therapy over the course of the study.
Several improvements were noted in the group receiving combination therapy. Average progression-free survival increased from 2.4 months in the single-drug group to 4.8 months in the combination group. There was a trend towards increased overall survival (23.9 to 28.5 months on average) but this difference was not statistically significant.
The investigators are delighted with the results, pointing out that "in breast cancer there are not many trials that show double progression-free survival."
The combination therapy was well tolerated, stated Dr Kaufman. "Treatment with anastrozole and trastuzumab was manageable, with no new or unexpected adverse events," she continued. "Further analysis is ongoing to better understand this patient population." She added that the quality of life of these patients was likely to be higher than those receiving chemotherapy. While the results were received with enthusiasm at the conference, the authors did add a note of caution, emphasizing that this treatment modality is currently only thought suitable for women with estrogen receptor-and HER2-positive disease that is progressing slowly and who have had no prior treatment with aromatase inhibitors.
Those with prior aromatase inhibitor treatment must remain on trastuzumab only and those with rapidly progressing disease should still be treated with chemotherapy and trastuzumab. Childhood cancer survivors were twice as likely to deliver prematurely compared with a control group of their sisters. Radiation therapy to the pelvis was particularly associated with pregnancy problems, with mothers who had received the highest doses of radiation (< 500 cGy) to the uterus having 3.5-times the risk of preterm delivery and an increased risk of low birthweight and small-forgestational-age infants.
In a related editorial, Leslie R Shover points out that this study does not consider other pregnancy complications in childhood cancer survivors, such as miscarriage, and concludes that "given the complex terrain our young survivors need to traverse (with regard to fertility), we should design patient and professional educational materials that map out the paths to making informed decisions." In brief...
Interpregnancy weight change and risk of adverse pregnancy outcomes: a population-based study.
Villamor E, Cnattingius S: Lancet 368(9542), 1164-1170 (2006) .
Suggests that women gaining weight after their first pregnancy are more likely to suffer adverse outcomes in a subsequent pregnancy. The study assessed the outcomes of the first two pregnancies of 151,025 women. Women whose body mass index (BMI) increased by 3 units or more had an increased risk of gestational hypertension or diabetes, cesarean section, stillbirth, and large-for-gestational-age births compared with women who maintained their weight. Weight gain was associated with adverse outcomes even if the BMI prior to each pregnancy was within the healthy range. The authors call for more randomized trials of weight loss interventions prior to pregnancy.
Selective use of sentinel lymph node surgery during prophylactic mastectomy.
Cancer 107 (7), 1440-1447 (2006) . Shows that sentinel lymph node surgery is not necessary in most patients undergoing prophylactic mastectomy. This observational study followed 436 patients undergoing bilateral or contralateral prophylactic mastectomy, of whom 108 underwent sentinel lymph node surgery. Of these, occult cancer was detected in 5%, most of which were ductal carcinoma in situ. In addition, there were six cases of invasive lobular carcinoma and two cases of invasive ductal carcinoma. The authors suggest that, given the low probability of cancer and the potential adverse effects of the surgery, sentinel lymph node surgery be used only in women aged over 60 years or with a history of invasive cancer.
Amniotic-fluid embolism and medical induction of labour: a retrospective, population-based cohort study. Indicates that medical induction of labor results in almost twice the risk of amniotic fluid embolism, a rare but serious complication that can lead to maternal death. The researchers examined records from 3 million hospital deliveries in Canada to determine what factors were associated with amniotic fluid embolism. Medical induction was associated with an odds ratio of 1.8; however, absolute risk remains very small.
High risk of polycystic ovary syndrome in obese premenopausal women
A Spanish study has revealed that a higher than expected proportion of overweight or obese women suffer from polycystic ovary syndrome (PCOS).
"Surprisingly," write Francisco Alvarez-Blasco and colleagues "the prevalence of PCOS in otherwise unselected overweight or obese women is unknown, despite obesity being frequent in patients with PCOS." They went on to state "We conducted the present study to obtain an unbiased estimate of the prevalence of PCOS in unselected overweight and obese premenopausal women from Spain."
Of a total of 113 women seeking dietary treatment for overweight or obesity, 32 were diagnosed with PCOS on the basis of clinical or biochemical hyperandrogenism, oligoovulation and exclusion of other potential causes.
"Our results demonstrate a 28.3% prevalence of PCOS in overweight and obese women from Spain, which is markedly increased compared with the 5.5% prevalence of PCOS in lean women of our country," the authors write. "Moreover, the increased prevalence of PCOS was found in overweight and obese women irrespective of the degree of obesity and independently from the presence or absence of the metabolic syndrome and its individual criteria."
The authors conclude that "Physicians treating overweight and obese patients should be aware of the high prevalence of PCOS among these women and that screening for PCOS, at least by obtaining a detailed menstrual history and a careful clinical evaluation of hyperandrogenic symptoms, should be conducted routinely to diagnose PCOS." 
Hormone effective for the treatment of vulvovaginal atrophy in postmenopausal women

Data presented at the 62nd Annual Meeting of the American Society for Reproductive Medicine suggest that oral synthetic conjugated estrogen-B (SCE-B), sold under the trade name Enjuvia ® , could relive symptoms of vulvovaginal atrophy in postmenopausal women.
A total of 310 postmenopausal women aged 30-80 years with at least one symptom of vaginal atrophy were enrolled in this randomized, multicenter, double-blind, placebocontrolled trial. They were randomly assigned to receive either placebo or SCE-B (0.3 mg/day) for 12 weeks. At baseline and end of study patients were evaluated for vaginal maturation index and vaginal pH and were asked to rate the severity of their "most bothersome symptoms."
The group receicing SCE-B, which is already used to treat menopausal symptoms (e.g., hot flushes), showed greater improvements in all end points than the placebo group, with no increase in side effects. The authors conclude that "A 0.3-mg tablet of SCE-B taken daily is effective in treating vulvovaginal atrophy in symptomatic postmenopausal women."
As with any estrogen-containing product, however, a small increased risk of adverse events is assumed with long-term use and must be weighed against the improvement in symptoms.
Source: ASRM 62nd Annual Meeting:
Abstract O-209. Presented October 24, 2006. 
BULLETIN BOARD
Aromatase inhibitors improve survival in advanced breast cancer
The results of a study analyzing the pooled data from trials involving over 8500 patients show that third-generation aromatase inhibitors are the best option for hormonal treatment of advanced breast cancer.
Third-generation aromatase inhibitors and inactivators, such as vorazole and anastrazole, conferred a significant survival advantage compared with older hormonal treatments, such as tamoxifen, according to the pooled results of 23 separate trials.
"The meta-analysis shows with largescale evidence that third-generation aromatase inhibitors and inactivators are superior in terms of survival when compared against standard hormonal therapy," summarized senior investigator John PA Ioannidis.
Dr Ioannidis went on to state that "The current evidence seems to be in favor of these agents replacing tamoxifen as the treatment of choice for first-line therapy in women with advanced breast cancer."
In a related editorial Daniel F Hayes points out that aromatase inhibitors are increasingly being incorporated into adjuvant treatment of breast cancer. "In the adjuvant setting, we need to decide for whom and when tamoxifen might be preferable to an aromatase inhibitor," concludes Dr Hayes. "In the metastatic setting, we need to determine if tamoxifen is effective if patients recur after taking adjuvant aromatase inhibitors."
Another recent study aimed to clarify which patients would benefit from the addition of aromatase inhibitors after adjuvant treatment with tamoxifen. A total of 471 women who were treated with surgery and radiation therapy followed by 5 years of tamoxifen were followed for an average of 8.25 years.
In these women, 36 relapses or contralateral breast cancers were reported. The investigators calculated that, assuming a 40% decreased risk of recurrence or contralateral breast cancer with the addition of a course of aromatase inhibitors, the additional reduction in risk would be only 1-2% overall, with slightly higher risk reductions in premenopausal women and those with four or more positive lymph nodes.
"Based upon our findings," the authors conclude, "women who are premenopausal at the time of initial therapy and patients who have four or more positive lymph nodes will have the greatest potential benefit from the addition of extended adjuvant anti-estrogen therapy." Natl Cancer Inst. 98, 1285 -1291 (2006 . 
European Medicines Agency strongly criticized over lack of women in clinical trials
Spanish researchers have claimed that women are underrepresented and unprotected in European drug trials, and that the European Medicines Agency (EMEA) is not doing enough to redress this imbalance.
In an editorial in a recent issue of the Journal of Epidemiology and Community Health, Maria T Ruiz Cantero and Maria A Pardo write that it is "worrisome" that, while the EMEA has acknowledged that "gender-specific influences…may be important when considering potential differences in response between men and women", it does not feel that separate guidelines for women are necessary or that the underrepresentation of women in early stage drug trials is relevant.
The researchers warn that "when women are excluded, any specific dosing requirements for them will remain undiscovered until much later in the drug development process, if ever," and feel that the EMEA needs to make more effort to ensure that drugs are shown to be safe and effective in both men and women. 
New biomarker of gestational hypertension
Researchers from the University of Hong Kong have revealed that plasma and urinary markers of oxidative stress measured in midpregnancy can help to predict the risk of gestational hypertension in later pregnancy. A sample of 388 women with singleton pregnancies underwent testing for oral glucose tolerance, plasma and urine 8-isoPGF2α (an isoprostane) levels and blood pressure at 24-32 weeks' gestation. 8-isoPGF2α levels were also tested at 34-37 weeks in 381 women. Of these, 17 women (4.2%) developed gestational hyerptension or pre-eclampsia Plasma 8-isoPGF2α appears to be a sensitive predictor of gestational hypertension and pre-eclampsia when measured at 24-32 weeks gestation; however, the authors point out that its "ability to discriminate deteriorates as pregnancy advances."
